|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS |
|
|
|
|
|
|
Comparing PSMA Ligands for Prostate Cancer Imaging
|
|
Michael Hofman, MBBS, FRACP, FAANMS, FICIS, GAICD
|
| Alicia Morgans discusses advances in prostate cancer imaging and theranostics with Michael Hofman. Dr. Hofman emphasizes the growing variety of PSMA ligands for PET-CT imaging and treatment, comparing their subtle differences and implications for clinical practice.
|
|
|
|
|
|
|
|
|
|
|
|
|
CLARIFY Trial: Advancing Prostate Cancer Imaging with 64Cu-SAR-bisPSMA PET
|
|
Neal Shore, MD, FACS
|
| Neal Shore discusses a new 64Cu-SAR-bisPSMA PET diagnostic agent for prostate cancer imaging with Phillip Koo. Dr. Shore highlights the unique features of this compound, including its bivalent structure and longer half-life compared to existing PSMA PET agents.
|
|
|
|
|
|
|
|
|
|
|
|
|
INDICATE Trial Seeks to Clarify Role of PET Scans in Prostate Cancer Recurrence
|
|
Neha Vapiwala, MD, FACR, FASTRO
|
| Alicia Morgans interviews Neha Vapiwala about the innovative phase three INDICATE trial, supported by the ECOG-ACRIN Group and NCI designated cooperative groups. The trial focuses on patients with biochemical recurrence after prostatectomy, examining the impact of PET scans on treatment decisions.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EDITOR SELECTED ABSTRACTS AND COMMENTARIES |
|
|
|
|
| 68Ga-P16-093 Diagnostic Performance in Newly Diagnosed Prostate Cancer- Histopathologic Correlation
|
| Jiarou Wang, MD
|
| At the 2024 SNMMI annual meeting, Dr. Jiarou Wang discussed the diagnostic performance of 68Ga-P16-093 in newly diagnosed prostate cancer. 68Ga-P16-093 is a novel PSMA-targeted radiopharmaceutical that has a labeling reaction compatible with various Ge/Ga generators and has a simple labeling method of heating at 95 degrees Celsius for 5 minutes, leading to high radiochemical purity.
|
|
|
|
|
|
| Impact of 18F-DCFPyL on Accuracy of mpMRI in Men with Low and Intermediate Risk Prostate Cancer: Interim Analysis of a Phase II Diagnostic Trial
|
| Marcelo Bigarella, MD
|
| The 2024 AUA Annual Meeting was host to an imaging/uroradiology poster session. Dr. Marcelo Bigarella presented the interim analysis of a phase II diagnostic trial assessing the impact of 18F-DCFPyL on the accuracy of mpMRI in men with low- and intermediate-risk prostate cancer.
|
|
|
|
|
|
| Artificial Intelligence: Innovation and Potential for Diagnostic Imaging in Prostate Cancer
|
| Stephanie A. Harmon, PhD
|
| The 2024 ASCO annual meeting featured a session on applications of artificial intelligence in prostate cancer care, and a presentation by Dr. Stephanie Harmon discussing innovation and potential for diagnostic imaging in prostate cancer. There are many opportunities for artificial intelligence in prostate imaging
|
|
|
|
|
|
|
|
|
|
|
| PSMA Radioligand Therapy in Patients with Prostate Cancer: Technical Considerations for Diagnostic, Quantitative, and Dosimetric Imaging
|
| John A. Kennedy, PhD
|
| At the 2024 SNMMI annual meeting Dr. John Kennedy discussed technical considerations for diagnostic, quantitative, and dosimetric imaging for PSMA radioligand therapy in patients with prostate cancer. Dr. Kennedy started by highlighting that radiolabeled small molecules targeting PSMA are used for diagnostic imaging and treatment
|
|
|
|
|
|
| Updates in Prevention, Diagnostics and Surgery: PSMA PET Updates
|
| Adam Weiner, MD
|
| The 2024 AUA Annual Meeting was host to the International Prostate Forum. Dr. Adam Weiner presented the latest advances in the prevention, diagnostic, and surgical applications of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in prostate cancer.
|
|
|
|
|
|
|
|
